Equities researchers at Leerink Swann started coverage on shares of 89bio (NASDAQ:ETNB) in a research note issued to investors on Monday, The Fly reports. The firm set an “outperform” rating on the stock.
A number of other equities analysts have also recently weighed in on ETNB. Bank of America started coverage on shares of 89bio in a research report on Monday. They set a “neutral” rating for the company. Royal Bank of Canada began coverage on shares of 89bio in a report on Monday. They set an “outperform” rating on the stock.
89bio stock opened at $28.60 on Monday. 89bio has a 1 year low of $16.60 and a 1 year high of $46.19.
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 that is being developed for the treatment of nonalcoholic steatohepatitis.
Recommended Story: Current Ratio
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.